Yokneam, Israel, October 7th, 2021 ̶ Butterfly Medical is proud to announce the addition of Joel Chechik as Chief Commercial Officer. Chechik will spearhead Butterfly’s commercial preparation for the United States launch of its breakthrough butterfly-shaped implant to reduce or eliminate benign prostatic hyperplasia (BPH) symptoms. BPH is a condition where the prostate enlarges and is most commonly seen in men, 50+ years old. Based in Minneapolis, Chechik will focus on Butterfly’s pre-FDA clinical site efforts, including site selection, enrollment and fulfillment of Butterfly’s Pre-Market Study and the development of a U.S. Commercialization plan.
“I’m extremely excited to join Butterfly Medical. With millions of men remaining under-served by pills or other failed treatment options, I believe our platform is poised to further disrupt the BPH arena. I’ve been amazed at its simplicity and ease in a quick, office procedure,” commented Mr. Chechik.
Chechik brings more than 25 years of multi-disciplinary experience in strategy, sales, marketing and business development for global medical device companies in urology-related fields. He previously held roles at NeoTract, Coloplast, Boston Scientific and most recently, a similar Israeli (Women’s Health) start-up, FEMSelect.
“As we move towards the next step in our clinical and commercialization plan, we are thrilled to have Joel on board. His vast expertise in the urology sector and his strong track record in leading a plethora of market development projects, innovation programs, product launches and merger integrations, will be essential as we grow our commercial capabilities,” said Idan Geva, CEO, Butterfly Medical.
BPH is a common condition in which a man has obstructive or irritative aspects of bladder and urination hurdles including: urgency, getting-up in the night, difficulty with bladder emptying and other concerning symptoms. Today, over 12-million men search for BPH treatment on an annual basis. Butterfly provides a much-needed treatment option, by focusing on the truly obstructive aspects of BPH.
Butterfly’s first product, a butterfly-shaped nitinol implant, is fully internal in the male anatomy and opens to widen the prostate’s compressive pressure on the prostatic-urethra. The quick, office-based (or outpatient) procedure usually takes less than six or seven minutes. Positive early results suggest high efficacy and a solid safety profile.
About Butterfly Medical
Butterfly Medical was founded in late 2014, as part of the portfolio of Alon Medtech Ventures’ incubator, with the goal of developing a non-surgical treatment for men suffering from BPH symptoms. The company was founded by Mr. Yehuda Bachar, a seasoned entrepreneur in the medical device space. The technology developed by the company allows for the procedure to be transferred from the operating room to the clinic, eliminating the need for hospitalization, and significantly shortening recovery time. For more information, see http://www.butterfly-medical.com.